Loading…

Aptamer-Mediated Targeted Delivery of Therapeutics: An Update

The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their abili...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals 2016-11, Vol.9 (4), p.69
Main Authors: Catuogno, Silvia, Esposito, Carla L, de Franciscis, Vittorio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353
cites cdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353
container_end_page
container_issue 4
container_start_page 69
container_title Pharmaceuticals
container_volume 9
creator Catuogno, Silvia
Esposito, Carla L
de Franciscis, Vittorio
description The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.
doi_str_mv 10.3390/ph9040069
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_82ce1bc9ef3c429ab5bb1748340c443a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_82ce1bc9ef3c429ab5bb1748340c443a</doaj_id><sourcerecordid>1839130446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</originalsourceid><addsrcrecordid>eNpdkV1rFDEUhoNYbLt64R-QAW_0YmxOPiYZocLSqi1UvNleh0xyZneW2cmYzBT67027dWmFQA7Jw5OXvIS8B_qF85qejZuaCkqr-hU5AcFEqZlQr5_Nx-Q0pS2lUoGAN-SYKZ2Xqk7I-XKc7A5j-Qt9Zyf0xcrGNT4Ml9h3dxjvi9AWqw1GO-I8dS59LZZDcTv6TL8lR63tE7572hfk9sf31cVVefP75_XF8qZ0ksupVMK7ygur0NumBUYrJUArZKCZhha8t4qjZI5bTitBuQMrK_TIOGs9l3xBrvdeH-zWjLHb2Xhvgu3M40GIa2Njztaj0cwhNK7GljvBatvIpgElNBfUCZEfWJBve9c4Nzv0Docp2v6F9OXN0G3MOtwZCbWmWbEgn54EMfyZMU1m1yWHfW8HDHMyoHkNPJNVRj_-h27DHIf8VZmSmjMJSmfq855yMaQUsT2EAWoeCjaHgjP74Xn6A_mvUf4XOeufLg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1858325178</pqid></control><display><type>article</type><title>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>IngentaConnect Journals</source><creator>Catuogno, Silvia ; Esposito, Carla L ; de Franciscis, Vittorio</creator><creatorcontrib>Catuogno, Silvia ; Esposito, Carla L ; de Franciscis, Vittorio</creatorcontrib><description>The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph9040069</identifier><identifier>PMID: 27827876</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>aptamers ; Cancer ; drug delivery ; Drug delivery systems ; Ligands ; Medical research ; Neurological disorders ; Review ; targeted therapy</subject><ispartof>Pharmaceuticals, 2016-11, Vol.9 (4), p.69</ispartof><rights>Copyright MDPI AG 2016</rights><rights>2016 by the authors; licensee MDPI, Basel, Switzerland. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</citedby><cites>FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1858325178/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1858325178?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25753,27922,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27827876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Catuogno, Silvia</creatorcontrib><creatorcontrib>Esposito, Carla L</creatorcontrib><creatorcontrib>de Franciscis, Vittorio</creatorcontrib><title>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</title><title>Pharmaceuticals</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.</description><subject>aptamers</subject><subject>Cancer</subject><subject>drug delivery</subject><subject>Drug delivery systems</subject><subject>Ligands</subject><subject>Medical research</subject><subject>Neurological disorders</subject><subject>Review</subject><subject>targeted therapy</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkV1rFDEUhoNYbLt64R-QAW_0YmxOPiYZocLSqi1UvNleh0xyZneW2cmYzBT67027dWmFQA7Jw5OXvIS8B_qF85qejZuaCkqr-hU5AcFEqZlQr5_Nx-Q0pS2lUoGAN-SYKZ2Xqk7I-XKc7A5j-Qt9Zyf0xcrGNT4Ml9h3dxjvi9AWqw1GO-I8dS59LZZDcTv6TL8lR63tE7572hfk9sf31cVVefP75_XF8qZ0ksupVMK7ygur0NumBUYrJUArZKCZhha8t4qjZI5bTitBuQMrK_TIOGs9l3xBrvdeH-zWjLHb2Xhvgu3M40GIa2Njztaj0cwhNK7GljvBatvIpgElNBfUCZEfWJBve9c4Nzv0Docp2v6F9OXN0G3MOtwZCbWmWbEgn54EMfyZMU1m1yWHfW8HDHMyoHkNPJNVRj_-h27DHIf8VZmSmjMJSmfq855yMaQUsT2EAWoeCjaHgjP74Xn6A_mvUf4XOeufLg</recordid><startdate>20161103</startdate><enddate>20161103</enddate><creator>Catuogno, Silvia</creator><creator>Esposito, Carla L</creator><creator>de Franciscis, Vittorio</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161103</creationdate><title>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</title><author>Catuogno, Silvia ; Esposito, Carla L ; de Franciscis, Vittorio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>aptamers</topic><topic>Cancer</topic><topic>drug delivery</topic><topic>Drug delivery systems</topic><topic>Ligands</topic><topic>Medical research</topic><topic>Neurological disorders</topic><topic>Review</topic><topic>targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Catuogno, Silvia</creatorcontrib><creatorcontrib>Esposito, Carla L</creatorcontrib><creatorcontrib>de Franciscis, Vittorio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Catuogno, Silvia</au><au>Esposito, Carla L</au><au>de Franciscis, Vittorio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</atitle><jtitle>Pharmaceuticals</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2016-11-03</date><risdate>2016</risdate><volume>9</volume><issue>4</issue><spage>69</spage><pages>69-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>27827876</pmid><doi>10.3390/ph9040069</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1424-8247
ispartof Pharmaceuticals, 2016-11, Vol.9 (4), p.69
issn 1424-8247
1424-8247
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_82ce1bc9ef3c429ab5bb1748340c443a
source PubMed (Medline); Publicly Available Content Database; IngentaConnect Journals
subjects aptamers
Cancer
drug delivery
Drug delivery systems
Ligands
Medical research
Neurological disorders
Review
targeted therapy
title Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A39%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aptamer-Mediated%20Targeted%20Delivery%20of%20Therapeutics:%20An%20Update&rft.jtitle=Pharmaceuticals&rft.au=Catuogno,%20Silvia&rft.date=2016-11-03&rft.volume=9&rft.issue=4&rft.spage=69&rft.pages=69-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph9040069&rft_dat=%3Cproquest_doaj_%3E1839130446%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1858325178&rft_id=info:pmid/27827876&rfr_iscdi=true